This product corresponds to purified 'native' human C1q. Its sequence is not determined in-house. Please refer to published sequences, e.g. in GenBank for UniProt accession nos. P02745, P02746, & P02747.
C1740
Complement component C1q from human serum
≥95% (SDS-PAGE)
Synonym(s):
C1q from human serum
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Pricing and availability is not currently available.
Recommended Products
General description
C1q, together with C1r and C1s, in the ratio of 1:2:2, form the C1 complex which is the first component of the classical complement pathway. C1q is composed of 18 polypeptide chains (six A, six B, six C) (MW 460 kDa). All contain an 81-aa collagen-like region composed of (Gly-Xaa-Yaa) repeating sequences close to the N-terminus. Three chains (A1B1C1) form a triple helix with the C-terminus forming the globular heads which may be structurally and functionally distinct domains.
Application
Complement component C1q is an important regulator factor for platelet activation. This has been a topic for research, as platelet-leukocyte aggregates play an important role in inflammatory conditions such as coronary heart disease. In particular, C1q has been shown to inhibit collagen induced aggregation and enhance production of reactive oxygen species (ROS).
Biochem/physiol Actions
C1q deficiency, either because of rare homozygous genetic defect, or transcriptional/translational defects, is almost certainly a cause of systemic lupus erythematosus (SLE). The three C1q subunits are expressed through a novel mechanism of transcriptional synchronization.
Physical form
Supplied as a solution in 10 mM HEPES, 300 mM NaCl, pH 7.2
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern.
Inbal Farkash et al.
Cell reports, 37(11), 110114-110114 (2021-12-10)
Messenger RNA-based vaccines against COVID-19 induce a robust anti-SARS-CoV-2 antibody response with potent viral neutralization activity. Antibody effector functions are determined by their constant region subclasses and by their glycosylation patterns, but their role in vaccine efficacy is unclear. Moreover
Consol Farrera et al.
Journal of immunology (Baltimore, Md. : 1950), 191(5), 2647-2656 (2013-08-02)
Neutrophil extracellular traps (NETs) facilitate the extracellular killing of pathogens. However, in recent years, excessive NET formation has been implicated in several pathological conditions. Indeed, NETs that are not removed from tissues or from the circulation might serve to trigger
Andrew D Greenhalgh et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(18), 6316-6322 (2014-05-03)
Macrophages in the injured spinal cord arise from resident microglia and infiltrating, peripherally derived monocytes. It is still not clear if macrophages derived from these two populations differ in their roles after CNS injury. The aims of this study are
Maria Del Pilar Martinez Viedma et al.
Viruses, 13(7) (2021-08-11)
Zika virus (ZIKV) is a mosquito-borne Flavivirus with a positive-sense RNA genome, which are generally transmitted through the bite of an infected Aedes mosquito. ZIKV infections could be associated with neurological sequelae that, and otherwise produces similar clinical symptoms as
Christian S Lobsiger et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(46), E4385-E4392 (2013-10-31)
Accumulating evidence from mice expressing ALS-causing mutations in superoxide dismutase (SOD1) has implicated pathological immune responses in motor neuron degeneration. This includes microglial activation, lymphocyte infiltration, and the induction of C1q, the initiating component of the classic complement system that
-
I ordered the C1740-1MG with lot#0000356664. I would like to know the protein sequences and the extinction coefficient about this protein?
1 answer-
Helpful?
-
-
Is this product suitable for use in cell cultures?
1 answer-
This product has not been tested for suitability in cell culture. The end user will need to determine suitability. However, there are multiple publications citing the use of this product in cell culture applications. Please see the link below to review an example:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377823/Helpful?
-
-
Hola, me gustaría saber como se reconstituye el producto para su uso en ensayos. Gracias.
1 answer-
This product is not suitable for use in clinical trials. Unless otherwise stated, this product is intended for research use only. It is not suitable for any other purpose, which includes, but is not limited to, unauthorized commercial use, in vitro diagnostic use, or therapeutic use in humans or animals.
Helpful?
-
-
What is the concentration of C1740?
1 answer-
The product is supplied at a concentration of approximately 1 mg/ml. The exact concentration is lot specific and reported on the Certificate of Analysis.
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
